For the best video experience, please use a Chrome or Firefox browser
In turn, its emerging market equity team had specific concerns over the investment case in Lippo Kawaraci, an Indonesian property developer. Had the view on the stock now changed?
A different, company-specific threat was identified in China with the GlaxoSmithKline bribery scandal meaning questions needed to be asked over holdings in another pharma company, Roche. Given Roche’s operations in China, was it similarly exposed?
The responsible investment team led the dialogue to reassess the investment case along with European, emerging market and global equity managers.
